Table 4 Comparison of the backgrounds of dapagliflozin group with or without amelioration of MAGE
Variables | Dapagliflozin (n = 14) | p value | |
|---|---|---|---|
Amelioration (Δ MAGE < 0) (n = 6) | Deterioration (Δ MAGE ≥ 0) (n = 8) | ||
Baseline MAGE (mg dL−1) | 100.2 ± 25.3 | 75.3 ± 29.2 | 0.11 |
Age (years) | 62.7 ± 8.9 | 63.3 ± 7.3 | 0.90 |
BMI (kg m−2) | 25.9 ± 4.7 | 26.9 ± 4.9 | 0.71 |
Duration of disease (years) | 16.7 ± 4.5 | 17.5 ± 10.0 | 0.84 |
HbA1c (%) | 7.0 ± 0.5 | 7.2 ± 1.0 | 0.65 |
1,5-Anhydro-d-glucitol (μg mL−1) | 8.3 ± 4.5 | 8.8 ± 5.1 | 0.85 |
ALT (IU L−1) | 42.2 ± 39.7 | 35.8 ± 22.6 | 0.73 |
Estimated GFR [mL min−1 (1.73 m2)−1] | 79.7 ± 12.5 | 62.2 ± 11.7 | 0.02 |
The total insulin dose (U) | 21.7 ± 21.3 | 13.1 ± 7.8 | 0.38 |